Make-whole redemption amount Notice to the Bondholders

16 June 2021

EUROFINS SCIENTIFIC S.E.

(a société européenne established in Luxembourg with its registered office at 23, Val Fleuri, L-1526, Luxembourg and registered with the Register of Commerce and Companies of Luxembourg under number B 167.775) (the "**Issuer**") acting through its French Branch

Subject: Make-whole redemption amount notice to Bondholders of the EUR 500,000,000 3.375% senior notes due 30 January 2023 (ISIN Code: XS1268496640) with a nominal amount outstanding of EUR 167,531,000 (the “**Notes**”)

We refer to the terms and conditions (the “**Conditions**”) of the Notes issued by the Issuer, acting through its French Branch, on 30 July 2015. Capitalized terms used but not defined in this Notice shall be as defined in the Conditions.

Pursuant to Conditions 6 (b)(ii) (*Redemption at the Make-whole Redemption Amount*) and 15 (*Notices*) of the Conditions of the Notes, the Issuer, acting through its French Branch, gave notice to the Bondholders on 21 May 2021 that it will redeem all of the Notes outstanding at the Make-whole Redemption Amount on 21 June 2021 (the “**Make-whole Redemption Date**”).

On the 15 June 2021 at 11.00 a.m. CET and in accordance with the provisions of Condition 6(b)(ii) (*Redemption at the Make-whole Redemption Amount*) of the Notes, the Make-Whole Redemption Amount has been calculated by the Calculation Agent:

- Early Redemption Rate: -0.695750%
- Early Redemption Margin: +0.50%
- The sum of the Early Redemption Rate and the Early Redemption Margin being the “**Make-whole Redemption Rate**”: -0.195750%
- Make-Whole Redemption Amount per Note: EUR 107,079.29 (including accrued interests of the Notes of EUR 1,313.00 per Note until, but excluding, the Make-whole Redemption Date).

Notes to Editors:

For more information, please visit www.eurofins.com **or contact:**

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 24 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.